Theorem Clinical Research

Drug Sponsors

Sorrento acquires Sherrington Pharmaceuticals

Friday, October 11, 2013 01:01 PM

Sorrento Therapeutics, a publicly-traded, development-stage biopharmaceutical company, has acquired Sherrington Pharmaceuticals, a privately-held company focused on the development of a chronic pain treatment for end-stage cancer patients and other severe pain indications.

More... »


Teva accelerates cost reduction program, to cut 5,000 jobs

Friday, October 11, 2013 01:00 PM

Global pharmaceutical company Teva Pharmaceutical Industries has accelerated its worldwide restructuring program, introduced in December 2012, which includes actions to divest non-core assets, increase organization effectiveness, improve manufacturing efficiency and reduce excess capacity.

More... »


Merck Serono opens global headquarters in Germany

Friday, October 11, 2013 12:58 PM

Merck Serono has opened new global headquarters in Darmstadt, Germany. The redesigned buildings feature an open office concept intended to encourage project work and collaboration. Of the 1,700 Merck Serono employees in Darmstadt, 800 work in two office buildings southeast of Merck's main campus.

More... »

PhRMA to open Middle East and Africa regional office at DuBiotech, UAE

Wednesday, October 9, 2013 02:09 PM

Pharmaceutical Research and Manufacturers of America (PhRMA) plans to establish its Middle East and Africa regional office within Dubai Biotechnology and Research Park (DuBiotech), a free zone dedicated to facilitating and fostering the growth of the life sciences industry in the UAE and a member of Tecom Investments, a developer and operator of business parks.

More... »

FDA postpones Advisory Committee meeting due to government shutdown

Wednesday, October 9, 2013 02:06 PM

ALK, a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment, has announced that due to the U.S. government shutdown, the FDA has temporarily postponed the Allergenic Products Advisory Committee meeting scheduled for Nov. 6 to discuss the Biologic License Application (BLA) for the investigational grass allergy immunotherapy (AIT) tablet. The FDA has not yet confirmed a new date for the Advisory Committee meeting.

More... »

Delcath Systems announces reorganization, 33% of workforce cut

Monday, October 7, 2013 03:54 PM

Delcath Systems, a specialty pharmaceutical and medical device company focused on oncology, has completed a strategic reorganization, eliminating 21 positions, or approximately 33% of its global workforce. The company expects this reorganization, in conjunction with other cost saving measures, to significantly lower cash utilization.

More... »

MedImmune completes acquisition of Amplimmune

Monday, October 7, 2013 02:52 PM

MedImmune, the global biologics R&D arm of AstraZeneca, completed its acquisition of Amplimmune, a privately-held, U.S.-based biologics company focused on developing novel therapeutics in cancer immunology.

More... »

Ben Venue Laboratories to cease production, cut all 1,100 jobs

Monday, October 7, 2013 01:33 PM

Ben Venue Laboratories, a Bedford, Ohio-based subsidiary of Boehringer Ingelheim that produces sterile injectables, has announced it will cease production by the end of 2013. Despite the ongoing support of the FDA, dedicated employees and investments in facility upgrades, the company cannot return to sustainable production.

More... »

Strathspey Crown acquires Evolus

Friday, October 4, 2013 01:26 PM

Strathspey Crown, a growth equity firm specializing in lifestyle healthcare, has acquired Evolus of Santa Barbara, Calif., for an undisclosed amount. Strathspey Crown's wholly-owned subsidiary Alphaeon, a lifestyle healthcare company, has received the exclusive license to market, in both the U.S. and several international markets, an advanced Botulinum toxin Type A neurotoxin developed by Daewoong Pharmaceutical, based in Seoul, South Korea. The Botulinum toxin Type A product will be marketed by Alphaeon under the brand name Evosyal. The exclusive license also includes certain rights associated with future neurotoxin developments by Daewoong Pharmaceutical.

More... »

Amgen completes Onyx merger

Wednesday, October 2, 2013 01:01 PM

Amgen has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Onyx Pharmaceuticals for $125 per share in cash. As announced Aug. 25, the purchase price is $9.7 billion net of estimated Onyx cash.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private á¼€nancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs